Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
J1P3
- Development stage
- Phase 2
- Lead developer
- Mayo Clinic
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravenous, Intraarticular
01
Overview
J1P3 is a lytic bacteriophage specifically targeting *Staphylococcus aureus*. It is utilized as a therapeutic agent in bacteriophage therapy, often as part of a cocktail (such as with phage BP13), to treat complex bacterial infections. J1P3 works by recognizing and binding to specific receptors on the surface of *S. aureus* cells, injecting its viral genome, and hijacking the host's cellular machinery to produce new phage particles. This process culminates in the lysis and destruction of the bacterial cell, releasing progeny phages to infect adjacent bacteria. This modality is particularly valuable for treating biofilm-associated infections, such as prosthetic joint infections, where bacteria are often protected from conventional antibiotics.
- Other names
- J1P3 bacteriophageJ-1P3 bacteriophageJ 1P3 bacteriophage
Beyond the preview
Go deeper on J1P3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on J1P3.